Edition:
United States

Bayer AG (BAYRY.PK)

BAYRY.PK on OTC Markets Group

131.91USD
23 May 2017
Change (% chg)

-- (--)
Prev Close
$131.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,862
52-wk High
$132.80
52-wk Low
$91.53

BAYRY.PK

Chart for BAYRY.PK

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $109,686.70
Shares Outstanding(Mil.): 826.95
Dividend: 2.96
Yield (%): 2.24

Financials

  BAYRY.PK Industry Sector
P/E (TTM): 20.87 14.29 17.36
EPS (TTM): 6.32 -- --
ROI: 8.57 -7.57 -5.72
ROE: 16.72 -7.17 -5.10

BRIEF-Evotec receives milestone as part of alliance with Bayer

* Evotec receives pre-clinical milestone as part of its endometriosis alliance with Bayer

May 22 2017

Fitch Publishes 'BBB' Syngenta Rating, Outlook Stable

(The following statement was released by the rating agency) LONDON, May 19 (Fitch) Fitch Ratings has published a 'BBB' Foreign-Currency Long-Term Issuer Default Rating on Syngenta AG following its takeover by China National Chemical Corporation (ChemChina; A-/Stable). At the same time, Fitch has published a Foreign-Currency Short-Term Issuer Default Rating on the company of 'F3' and a senior unsecured long-term rating of 'BBB'. A full list of rating actions is at the end of this commentary. The

May 19 2017

Bayer gets FDA priority review for blood cancer drug

FRANKFURT, Germany German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.

May 17 2017

Bayer gets FDA priority review for blood cancer drug

FRANKFURT, Germany German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.

May 17 2017

Bayer gets FDA priority review for blood cancer drug

FRANKFURT, Germany, May 17 German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.

May 17 2017

BRIEF-FDA grants Bayer priority review for investigational compound Copanlisib

* FDA grants Bayer priority review for investigational compound Copanlisib in Follicular Lymphoma

May 17 2017

BRIEF-FDA grants priority review to Bayer anti-cancer compound

* Says receives FDA priority review for investigational anti-cancer compound copanlisib Further company coverage:

May 17 2017

Trump U.S. antitrust nominee says will be independent of White House

WASHINGTON Makan Delrahim, who was chosen by President Donald Trump to be the top U.S. antitrust regulator, said on Wednesday that he would maintain independence from the White House in enforcing antitrust law.

May 10 2017

Trump U.S. antitrust nominee says will be independent of White House

WASHINGTON Makan Delrahim, who was chosen by President Donald Trump to be the top U.S. antitrust regulator, said on Wednesday that he would maintain independence from the White House in enforcing antitrust law.

May 10 2017

Trump U.S. antitrust nominee says will be independent of White House

WASHINGTON Makan Delrahim, who was chosen by President Donald Trump to be the top U.S. antitrust regulator, said on Wednesday that he would maintain independence from the White House in enforcing antitrust law.

May 10 2017

More From Around the Web

Competitors

Earnings vs. Estimates